Full Press Release Details
dupixent dupilumab demonstrated superiority over xolair omalizumab in chronic rhinosinusitis with nasal polyps crswnp in patients with coexisting asthma in first ever presented pha.
REGN
dupixent dupilumab demonstrated superiority over xolair omalizumab in chronic rhinosinusitis with nasal polyps crswnp in patients with coexisting asthma in first ever presented pha
Key Takeaway: dupixent dupilumab demonstrated superiority over xolair omalizumab in chronic rhinosinusitis with nasal polyps crswnp in patients with coexisting asthma in first ever presented pha